Arsenal Medical wins $14m DoD contract

Arsenal Medical said today it won a contract from the U.S. Army Medical Research & Materiel Command worth more than $14 million to complete clinical and manufacturing development and regulatory submission for its ResQFoam. Arsenal’s ResQFoam is a self-expanding biomaterial designed to be administered at the point of injury to stop blood loss in patients with severe internal bleeding in the abdomen due to life-threatening traumas. The material fills the wound and conforms to the abdominal cavity to control bleeding and can be removed before surgery, the company said. “The strong governmental support we have received for this program has allowed Arsenal to complete a comprehensive and carefully executed development program that was ideally tailored to create a novel, life-sustaining product of this kind. We look forward to working with the U.S. Food and Drug Administration to ensure the timely review and availability of this critically important product for both civilian and military trauma care,” Arsenal research and development senior director Upma Sharma said in a prepared statement. The Watertown, Mass.-based company said the latest grant brings the total it has received from the Department of Defense up to $35 million. Arsenal said it has demonstrated preclinical proof of concept for the foam in a multi-center cadaver study where the foam was shown to be effective at filling the abdominal cavity when injected through the navel. “ResQFoam is desi...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Wound Care Arsenal Medical Source Type: news